Results 141 to 149 of about 36,471 (149)

The assessment of dupilumab in children with moderate-to-severe asthma and comorbid type 2 inflammatory diseases. [PDF]

BMC Pulm Med
Shi T, Wu S, Chen R, Xie Y, Yin G, He C, Liang C, Lu G.   +7 more
europepmc   +1 more source

Relationship Between Bronchodilator Reversibility and Spirometry Response to Dupilumab in Type 2 High Uncontrolled Severe Asthma. [PDF]

Clin Exp Allergy
Greig R, Stewart K, Kuo CR, Chan R, Lipworth B.   +4 more
europepmc   +1 more source

Association between impaired diffusion capacity and small airway dysfunction: a cross-sectional study. [PDF]

ERJ Open Res
Zhou K, Wu F, Lu L, Tang G, Deng Z, Dai C, Zhao N, Wan Q, Peng J, Wu X, Zeng X, Cui J, Yang C, Chen S, Huang Y, Yu S, Zhou Y, Ran P.   +17 more
europepmc   +1 more source

Time is lung: higher preservation of lung function in severe asthma patients after earlier mepolizumab treatment. [PDF]

ERJ Open Res
González-Barcala FJ, Bobolea I, Domínguez-Ortega J, Bañas-Conejero D, Antelo-Cea E, Martínez-Moragón E, Carrillo-Díaz T, Blanco-Aparicio M, Domingo C.   +8 more
europepmc   +1 more source

Prevalence of Chronic Obstructive Pulmonary Disease and Asthma in the Community of Pathumthani, Thailand. [PDF]

Diseases
Saiphoklang N, Ruchiwit P, Kanitsap A, Tantiyavarong P, Vatcharavongvan P, Palungrit S, Leelasittikul K, Pugongchai A, Poachanukoon O.   +8 more
europepmc   +1 more source

Phenotyping Chronic Obstructive Pulmonary Disease Through Principal Component Analysis: Identification of Clinical Clusters. [PDF]

Cureus
Mekov EV, Yanev NA, Kurtelova N, Mihalova T, Tsakova A, Yamakova Y, Petkov RE.   +6 more
europepmc   +1 more source

The Rapidly Evolving Landscape of Asthma Therapies Is Exhilarating, Yet a Lack of Innovation in Clinical Trial Design Makes Feasibility A Real Concern. [PDF]

Am J Respir Crit Care Med
Lugogo N.
europepmc   +1 more source